STAT NewsOriginal article
STAT+: FDA to reconsider treatment for rare cancer after its surprise rejection
RegulatoryEbvalloPositive
AI Analysis
Summary
The FDA has agreed to reconsider its rejection of Ebvallo, a rare cancer treatment, after the developing companies reached an agreement to address the agency's primary concerns.
Outcome Details
FDA agreed to reconsider rejection; companies reached agreement to address main rejection reason
Importance:6/10
Sentiment:
0.60
FDARare DiseaseDrug RejectionRegulatory ReviewReconsideration
Read the original article
Published by STAT News on May 7, 2026 12:00 PM